| 1. |
Zhang J, Zhang J, Zhang C, et al. Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications[J/OL]. Cells, 2022, 11(21): 3362[2022-10-25]. https://pubmed.ncbi.nlm.nih.gov/36359761/. DOI: 10.3390/cells11213362.
|
| 2. |
戴虹, 盧穎毅. 糖尿病黃斑水腫治療策略的變化與面臨的問題[J]. 中華眼底病雜志, 2022, 38(1): 6-9. DOI: 10.3760/cma.j.cn511434-20220104-00007.Dai H, Lu YY. Advances in the treatment strategies of diabetic macular edema and the problems[J]. Chin J Ocul Fundus Dis, 2022, 38(1): 6-9. DOI: 10.3760/cma.j.cn511434-20220104-00007.
|
| 3. |
Amoaku WM, Cushley L, Silvestri V, et al. Vitreomacular interface abnormalities in the Ghanaian African[J]. Eye, 2024, 38(3): 578-584. DOI: 10.1038/s41433-023-02737-z.
|
| 4. |
Maguire M, Laidlaw D, Davies N, et al. The impact of vitreo-macular interface abnormalities on the response to anti-VEGF therapy for centre involving diabetic macular oedema[J]. Graefe's Arch Clin Exp Ophthalmol, 2024, 262(11): 3501-3508. DOI: 10.1007/s00417-024-06518-6.
|
| 5. |
Elkayal H, Bedda AM, El-Goweini H, et al. Pars plana vitrectomy versus intravitreal injection of ranibizumab in the treatment of diabetic macular edema associated with vitreomacular interface abnormalities[J/OL]. J Ophthalmol, 2021, 2021: 6699668[2021-01-12]. https://pubmed.ncbi.nlm.nih.gov/33520299/. DOI: 10.1155/2021/6699668.
|
| 6. |
中華醫學會糖尿病學分會. 中國2型糖尿病防治指南(2020年版)[J]. 中華糖尿病雜志, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.Chinese Diabetes Society of the Chinese Medical Association. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)[J]. Chin J Diabetes, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.
|
| 7. |
Duker JS, Kaiser PK, Binder S, et al. The international vitreomacular traction study group classification of vitreomacular adhesion, traction, and macular hole[J]. Ophthalmology, 2013, 120(12): 2611-2619. DOI: 10.1016/j.ophtha.2013.07.042.
|
| 8. |
Hsieh TC, Deng GH, Chang YC, et al. A real-world study for timely assessing the diabetic macular edema refractory to intravitreal anti-VEGF treatment[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1108097[2023-05-17]. https://pubmed.ncbi.nlm.nih.gov/37265702/. DOI: 10.3389/fendo.2023.1108097.
|
| 9. |
Kirik F, Ersoz MG, Atalay F, et al. Outer retinal layer deterioration patterns in eyes with diabetic serous macular detachment[J]. Retina, 2025, 46(3): 425-437. DOI: 10.1097/IAE.0000000000004698.
|
| 10. |
Han YE, Jo J, Kim YJ, et al. Factors affecting intensive aflibercept treatment response in diabetic macular edema: a real-world study[J/OL]. J Diabetes Res, 2023, 2023: 1485059[2023-07-18]. https://pubmed.ncbi.nlm.nih.gov/37497120/. DOI: 10.1155/2023/1485059.
|
| 11. |
Zhou ZH, Zhao L, Wang YL, et al. Predictive impact of serous retinal detachment in refractory diabetic macular edema[J/OL]. BMC Ophthalmol, 2025, 25(1): 177[2025-04-07]. https://pubmed.ncbi.nlm.nih.gov/40197164/. DOI: 10.1186/s12886-025-03993-1.
|
| 12. |
Rabina G, Hilely A, Barequet D, et al. Epiretinal membrane in patients with diabetic macular edema[J]. Ophthalmologica, 2022, 245(5): 446-454. DOI: 10.1159/000524742.
|
| 13. |
Midena E, Torresin T, Schiavon S, et al. The disorganization of retinal inner layers is correlated to müller cells impairment in diabetic macular edema: an imaging and omics study[J/OL]. Int J Mol Sci, 2023, 24(11): 9607[2023-06-01]. https://pubmed.ncbi.nlm.nih.gov/37298558/. DOI: 10.3390/ijms24119607.
|
| 14. |
Vujosevic S, Alovisi C, Piccoli G, et al. Severity of disorganization of retinal layers and visual function impairment in diabetic retinopathy[J]. Ophthalmol Retina, 2024, 8(9): 880-888. DOI: 10.1016/j.oret.2024.04.005.
|
| 15. |
Eraslan S, Y?ld?r?m ?, Dursun ?, et al. Relationship between final visual acuity and optical coherence tomography findings in patients with diabetic macular edema undergoing anti-VEGF therapy[J]. Turk J Ophthalmol, 2020, 50(3): 163-168. DOI: 10.4274/tjo.galenos.2019.91962.
|
| 16. |
Meduri A, Oliverio GW, Trombetta L, et al. Optical coherence tomography predictors of favorable functional response in na?ve diabetic macular edema eyes treated with dexamethasone implants as a first-line agent[J/OL]. J Ophthalmol, 2021, 2021: 6639418[2021-03-24]. https://pubmed.ncbi.nlm.nih.gov/33833870/. DOI: 10.1155/2021/6639418.
|
| 17. |
付浴東, 孟旭霞, 王萍, 等. 不同光相干斷層掃描分型糖尿病黃斑水腫玻璃體腔注射雷珠單抗的療效差異及橢圓體帶完整性與視力相關性觀察[J]. 中華眼底病雜志, 2017, 33(2): 129-133. DOI: 10.3760/cma.j.issn.1005-1015.2017.02.005.Fu YD, Meng XX, Wang P, et al. Efficacy of intravitreal injection of ranibizumab for different patterns of optical coherence tomography of diabetic macular edema and the relationship between integrity of ellipsoidal zone and visual acuity outcomes[J]. Chin J Ocul Fundus Dis, 2017, 33(2): 129-133. DOI: 10.3760/cma.j.issn.1005-1015.2017.02.005.
|
| 18. |
Basiony AI, Mohamed Gad Marey H, Ezzat Abdel Fattah AM, et al. Predictive value of optical coherence tomography angiography in management of diabetic macular edema[J/OL]. BMC Ophthalmol, 2024, 24(1): 429[2024-10-01]. https://pubmed.ncbi.nlm.nih.gov/39354390/. DOI: 10.1186/s12886-024-03540-4.
|
| 19. |
Laz?r AS, Stanca HT, T?b?caru B, et al. Quantitative parameters relevant for diabetic macular edema evaluation by optical coherence tomography angiography[J/OL]. Medicina (Kaunas), 2023, 59(6): 1120[2023-06-10]. https://pubmed.ncbi.nlm.nih.gov/37374324/. DOI: 10.3390/medicina59061120.
|
| 20. |
El-Khoury S, Ngo C, Muraine M, et al. Pars plana vitrectomy and ILM peeling for refractory diabetic macular edema without vitreomacular traction[J/OL]. J Clin Med, 2025, 14(11): 3686[2025-05-24]. https://pubmed.ncbi.nlm.nih.gov/40507447/. DOI: 10.3390/jcm14113686.
|